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Introduction: Appearance of isolated reports of resistance to anti-methicillin-resistant
Staphylococcus aureus (MRSA) drugs is worrisome underscoring the need to continuously
monitor the susceptibility of clinical MRSA isolates to these drugs. Hence, the present study
is  conducted to determine the susceptibility of MRSA isolates to various classes of anti-MRSA
drugs such as vancomycin (glycopeptide), daptomycin (lipopeptide), tigecycline (glycylcy-
cline), and linezolid (oxazolidinone) to determine the MIC50 and MIC90 values, and to observe
MIC  creep over a three year period, if any, with respect to these drugs.
Methods: A total of 200 isolates of MRSA obtained from clinical specimens were included.
MIC was determined by E-test for anti-MRSA antibiotics vancomycin, linezolid, daptomycin,
and tigecycline. Non-parametric methods (Kruskal–Wallis and Chi-square test) were used
to  assess MIC trends over time. In addition, MIC50 and MIC90 values were also calculated.
Results: No isolate was found resistant to vancomycin, daptomycin, or linezolid; ﬁve isolates
were resistant to tigecycline. Seven VISA isolates were encountered with the MIC value for
vancomycin of 4 g/mL. MIC values for vancomycin, tigecycline, linezolid showed a deﬁ-
nite  increase over a 3-year period which was statistically signiﬁcant with p-values <0.0001,
0.0032, 0.0242, respectively. When the percentage of isolates with a median MIC value less
than  or equal to that of the index year was calculated, the change was most striking with
vancomycin. The proportion of isolates with higher MIC values was greater in 2014 than
2012 and 2013.
Conclusion: MIC creep was notably observed with vancomycin, and to some extent with tige-cycline and linezolid. Selection pressure may result in creeping MICs, which may herald the
emergence of resistant organisms.
© 2015 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail address: sujathasistla@gmail.com (S. Sujatha).
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Introduction
Vancomycin has been the mainstay of therapy for seri-
ous infections caused by methicillin-resistant Staphylococcus
aureus (MRSA), because of its relatively good safety proﬁle, its
low potential to induce resistance, and for many  years, the
lack of other approved alternatives.1 However, its efﬁcacy has
become uncertain, because of its slow bactericidal activity, the
emergence of isolates with reduced susceptibility and possible
“MIC creep” among susceptible strains.2
In the last few years, newer antibiotics such as linezolid,
daptomycin, tigecycline, dalbavancin, telavancin, oritavancin,
ceftobiprole, ceftaroline, and iclaprim have been added to
the arsenal of anti-MRSA drugs with many  of them already
in clinical use and some on the horizon. Linezolid is a syn-
thetic oxazolidinone that inhibits the initiation of protein
synthesis at the 50s ribosome and has bacteriostatic activ-
ity against MRSA. It is currently approved by the United
States Food and Drug Administration (US FDA) for the treat-
ment of complicated skin and skin-structure infections (SSSIs)
and nosocomial pneumonia caused by susceptible pathogens,
including MRSA.1 Daptomycin is a cyclic lipopeptide that
causes depolarization of the bacterial cell membrane and
has bactericidal activity. It is recommended for treatment of
skin and skin structure infections, bacteremia, and right-sided
endocarditis caused by MRSA, as well as patients with pro-
longed MRSA bacteremia, who are at high risk for metastatic
complications and death.3 Tigecycline is the ﬁrst glycylcy-
cline class of antibiotic which has bacteriostatic activity
against MRSA, has been approved by US FDA for the treat-
ment of complicated skin and skin structure infections (cSSSI)
and complicated intra-abdominal infections.4 Tigecycline can
overcome the two common mechanisms that are associated
with tetracycline resistance – ribosomal protection and efﬂux
pumps.5
Appearance of isolated reports of resistance to these
alternative drugs is worrisome underscoring the need to con-
tinuously monitor the susceptibility of clinical MRSA isolates
to these drugs. The present study was conducted to deter-
mine the susceptibility of MRSA isolates to various classes
of anti-MRSA drugs such as vancomycin (glycopeptide), dap-
tomycin (lipopeptide), tigecycline (glycylcycline) and linezolid
(oxazolidinone) to determine the MIC50 and MIC90 values and
to observe MIC  creep, if any, with respect to these drugs.
Table 1 – MIC50 and MIC90 of anti-MRSA drugs.
Antibiotics MIC values 2012
(n = 62)
Vancomycin MIC50 0.75 
MIC90 2 
Daptomycin MIC50 0.125 
MIC90 0.25 
Tigecycline MIC50 0.094 
MIC90 0.38 
Linezolid MIC50 0.19 
MIC90 1  1 5;1  9(6):585–589
Materials  and  methods
A total of 200 isolates of MRSA obtained from clinical spec-
imens (pus – 119; blood – 12; tissue bit – 9; pleural ﬂuid
– 2; tracheal aspirate – 4; wound swab – 40, and 14 from
other specimens) submitted to Department of Microbiology,
JIPMER, Puducherry from January 2012 to December 2014. The
isolates were almost equally distributed over the three-year
period – 2012 (62), 2013 (63), and 2014 (75). Only one isolate
per patient was included in the analysis. In case of multiple
isolates, the ﬁrst isolate was included. Minimum inhibitory
concentration (MIC) was determined by E-test for anti-MRSA
antibiotics vancomycin, linezolid, daptomycin, and tigecy-
cline, according to manufacturer’s instructions (bioMérieux,)
and the results were interpreted as per CLSI guidelines6
and EUCAST guidelines7 for tigecycline. For quality control,
Staphylococcus aureus ATCC 29213 was employed. Methicillin
resistance was conﬁrmed by PCR for mecA gene.
The percentage of isolates with a median MIC  value less
than or equal to that of the index year (2012) was calculated
for each antibiotic in the three years under study, to observe
changes in the proportion of isolates with lower MIC values,
which would suggest an “MIC creep”. In addition, MIC50 and
MIC90 values of vancomycin, linezolid, daptomycin, and tige-
cycline were also calculated.
Statistical  analysis
Chi-square test was employed for the assessment of signif-
icant change, if any, among the MIC values of isolates in
three years in comparison with the median MIC  value of the
index year (2012). MIC trends over the three years and the
signiﬁcance of changes in MIC values were assessed using
non-parametric Kruskal–Wallis test with the help of Graphpad
prism 6.0 software. p-Value <0.05 was considered signiﬁcant.
ResultsThe MIC values for vancomycin ranged from 0.125 to 3 mg/L,
for linezolid from 0.016 to 2 mg/L, for daptomycin from 0.016
to 0.5 mg/L, and for tigecycline from 0.016 to 1 mg/L. MIC50 and
MIC90 values are depicted in Table 1.
2013
(n  = 63)
2014
(n = 75)
Total
(n  = 200)
1 1.5 1
2 2 2
0.125 0.125 0.125
0.38 0.38 0.38
0.094 0.19 0.094
0.38 0.5 0.5
0.25 0.5 0.38
1.5 1.5 1.5
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Fig. 1 – Percentage of isolates with MIC  values less than or
equal to the index year (2012) median MIC  of differentb r a z j i n f e c t d i s .
No isolate was found resistant to vancomycin, daptomycin,
r linezolid. However, ﬁve isolates had MIC  values greater
han 0.5 mg/L for tigecycline, which is the susceptibility break-
oint for MRSA. Although, no resistance to vancomycin was
bserved, 9 isolates had the MIC  value of 3 mg/L, which falls
n the range of intermediate susceptibility. For conﬁrmation,
gar dilution was also performed and the MIC  value was found
o be 4 mg/L for 7 isolates. According to CLSI guidelines, those
solates were identiﬁed as vancomycin-intermediate S. aureus
VISA).
IC  creep
IC  values of vancomycin, tigecycline, and linezolid showed
 deﬁnite increase over a three-year period which was sta-
istically signiﬁcant with the p-values <0.0001, 0.0032, 0.0242,
espectively.
The 2012 median MIC  values for vancomycin, line-
olid, daptomycin, and tigecycline were 0.75 mg/L, 0.19 mg/L,
.125 mg/L, and 0.094 mg/L, respectively. When the percentage
f isolates with a median MIC  value less than or equal to that
f the index year was calculated, the change was most striking
ith vancomycin with the proportion being signiﬁcantly lower
n 2014 when compared to the preceding two years, indicating
hat “MIC creep” had indeed occurred (Fig. 1).As a further evidence for MIC  creep, the proportion of iso-
ates with higher MIC  values was greater in 2014 than 2012 and
013. This was again most notably observed with vancomycin
nd tigecycline, and to some extent with linezolid (Fig. 2A–C).
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Fig. 2 – Proportion of isolates with dantibiotics.
However, with daptomycin, the proportion of isolates with
lower MIC values was greater in 2014 when compared to the
previous years (Fig. 2D).
DiscussionFor more  than four decades, vancomycin has been the cor-
nerstone of therapy to treat serious infections caused by
MRSA, but the emergence of VISA, hVISA and VRSA has
B) Linezolid
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compromised its efﬁcacy. From India, only a few studies have
reported VISA/VRSA from different regions. An earlier study
from our hospital reported a single VISA with MIC 5 mg/L,
among 102 clinical isolates.8 In a study from Hyderabad, 16
VISA and 7 VRSA were reported out of 358 S. aureus isolates
tested.9 The overt presence of VISA/VRSA is only the tip of
the iceberg, whereas the greater danger is the phenomenon
of MIC  creep, which may herald the emergence of resistance
compromising the clinical utility of the antibiotic.
Although, none of the VISA isolates were from serious/life
threatening infections in the present study (all VISA isolates
were from skin and soft tissue infections) the point of concern
is that two of them were community acquired, raising the pos-
sibility of emergence and spread of VISA isolates outside the
hospital setting.
In any given microbial population, the central MIC ten-
dency can increase over time, and the phenomenon is termed
as MIC  “creep.” This phenomenon is inﬂuenced by many  fac-
tors, wherein clonal replacement and antibiotic exposure can
play a vital role. Failure rates exceeding 60% for S. aureus dis-
playing a vancomycin MIC  value of 4 mg/L prompted CLSI
recommendations to lower the breakpoint for susceptibility
from 4 to 2 mg/L, in 2006.10
The clinical impact of rising MICs of vancomycin could
not be accurately assessed, as most of those patients were
not treated with vancomycin although the association of
increased vancomycin MIC  and vancomycin treatment fail-
ures has been well documented worldwide. In the last decade,
many studies had demonstrated the association between
higher vancomycin MICs and poorer clinical outcomes, though
a few studies have shown no such association.11 In a meta-
analysis, Jacob et al. concluded that “a susceptible but high
MIC  to vancomycin is associated with increased mortality and
treatment failure among patients with MRSA infections”.12
Holmes et al. have demonstrated the association between
higher vancomycin MIC  and increased mortality in patients
with MRSA bacteremia13 and nosocomial pneumonia; Choi
et al. have demonstrated slower clinical response and higher
relapse rate than patients infected with low vancomycin MIC
isolates.14 Similarly, Maclayton et al. have also reported that
hemodialysis patients who had MRSA bacteremia with a van-
comycin MIC  of 2 mg/L experienced a longer mean hospital
length of stay and increased hospital costs compared with
patients with MRSA bacteremia with a vancomycin MIC less
than or equal to 0.5 mg/L.15
Using categorical representation of data such as percent-
age susceptible or breakpoint MICs, or even with traditional
percentile MIC  markers such as MIC50 and MIC90 values, there
is a strong likelihood that population shifts in MIC  values
will go undetected. Conventional CLSI recommended broth
dilution method might not be able to detect subtle changes. E-
Test, on the other hand, is capable of detecting these changes
by incorporating intermediate MIC  dilutions.16 Though E-test
has gained credibility for MIC  determination, higher MICs
observed in the present study should be interpreted with cau-
tion, as E-test has been reported to give higher MIC values than
2that of reference broth microdilution method. Study reports
have shown that E-test provides vancomycin and daptomycin
MIC  results consistently higher by 0.5–1.5 log2 dilutions than
those provided by precisely performed reference BMD tests.17 1 5;1  9(6):585–589
In this study, MIC50 and MIC90 values for vancomycin and
daptomycin were found to be 1 and 2 mg/L and 0.19 and
0.38 mg/L, respectively, which were comparable to the results
of the study reported from PGIMER, in 2014.18 MIC90 value
of daptomycin has been found a little higher in our study.
A recent study from Brazil has reported tigecycline and dap-
tomycin resistance in 10 and 2 MRSA isolates, respectively,
out of 36 isolates.19 Five of the MRSA isolates in the present
study exhibited higher MIC values for tigecycline above the
susceptibility breakpoint (≤0.5 mg/L), which is of concern. CLSI
recommendations are not available for the susceptibility test-
ing of S. aureus,  yet it is recommended by EUCAST. The ﬁnding
reported here, with reduced susceptibility to tigecycline was
therefore considered to be signiﬁcant.
The usage of vancomycin in our hospital has seen a marked
increase in the last decade while linezolid has been in limited
use (for skin and soft tissue infections) in the last two years
suggesting that selection pressure may be the underlying trig-
ger for the observed MIC creep for vancomycin and to some
extent for linezolid. The same may not hold true for dapto-
mycin and tigecycline as they are not a part of our hospital
formulary. However, patients’ prior exposure to these antibi-
otics cannot be ruled out.
None of the MRSA isolates in our study showed resis-
tance to daptomycin and linezolid. Daptomycin has been
studied by a number of investigators and has proved to be
effective for bacteremic infections due to staphylococci as
well as vancomycin-resistant enterococci and other Gram-
positive organisms.20 It has been hypothesized that antibiotics
which inhibit protein synthesis may be effective against sus-
ceptible toxin-producing strains. Recently, it has been found
in an in vitro model that linezolid, along with clindamycin,
reduce the production of Panton-Valentine leukocidin toxin,
alpha-hemolysin, and toxic-shock syndrome toxin-1.21 Hence,
treatment with linezolid might have an added advantage in
treating skin and soft-tissue infections caused by CA-MRSA,
which are toxin producers.
Although, no alarming rates of resistance to anti-MRSA
drugs was observed in our study, we should guard against com-
placence as a combination of selection pressure and creeping
MIC may result in the emergence of resistant organisms. This
study underscores the need for continuously monitoring the
shifts in MIC values even in the susceptible range. A limitation
of the study was the lack of data on clonality of isolates by
molecular typing methods such as PFGE or MLST. This would
have shed light on the spread of a particular clone with higher
vancomycin and linezolid MICs.
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